GameStop Eyes eBay Acquisition as Stock Prices Surge After Hours 
Samsung Appoints New TV Business Head Amid Rising Competition from Chinese Rivals 
Ford Q1 Earnings Beat Expectations, Stock Surges on Strong Guidance 
Meta Raises 2026 Capex Outlook Amid AI Spending Surge, Shares Drop After Earnings 
GameStop Proposes $56 Billion eBay Acquisition in Bold Strategic Move 
Hugo Boss Beats Q1 Profit Expectations Despite Market Headwinds 
Berkshire Hathaway Q1 Earnings Jump 18% as Greg Abel Signals Disciplined Growth Strategy 
United Airlines Flight Hits Light Pole During Newark Landing, FAA Investigates 
Amazon Stock Dips Despite Record Earnings as AI Infrastructure Spending Surges 
Coles Group Q3 Sales Rise Driven by Supermarkets and E-Commerce Growth 
Standard Chartered Q1 Profit Hits Record on Wealth and Investment Banking Growth 
Volvo Car Sales Drop 10% in Early 2026 Despite Growth in Electric Vehicles 
Anthropic Secures $1.5B AI Venture Backed by Wall Street Giants, Shaking Software Sector 
Intel Emerges as Key Contender in Apple’s Chip Manufacturing Strategy Shift 
SAN DIEGO, May 01, 2018 -- REVA Medical, Inc. (ASX:RVA) (“REVA” or the “Company”) has scheduled a conference call to review its first quarter 2018 financial results and provide a business update.
The call is scheduled for 2:00 p.m. US PDT on Wednesday, May 9, 2018 (which is 7:00 a.m. AEST on Thursday, 10 May 2018) and may be accessed within the United States and Canada by dialing 1-877-312-5413 five minutes prior to the scheduled start time. Callers within Australia may access the call toll-free by dialing 1800 005 989. The conference ID is 1993886 for all locations.
If you reside outside of the United States, Canada, or Australia, or if you prefer to access the call through our website, please visit “Events & Presentations” under the “Investors” section of our website at www.revamedical.com, and click on the “listen to webcast” link. A live webcast and transcript of the call will also be available on our website.
About REVA Medical
REVA Medical is a medical device company focused on the development and commercialization of bioresorbable polymer technologies for vascular applications. The Company’s lead products are the Fantom and Fantom Encore bioresorbable vascular scaffolds for the treatment of coronary artery disease. REVA is located in San Diego, California, USA and employs over 50 people in the U.S. and Europe.
Fantom and Fantom Encore are trademarks of REVA Medical, Inc.
| United States | Australia | Australia | |
| Investor & Media Enquiries: | Investor Enquiries: | Media Enquiries: | |
| REVA Medical, Inc. | Inteq Limited | Buchan Consulting | |
| Brandi Roberts | Kim Jacobs | Rebecca Wilson | |
| Chief Financial Officer | +61 438 217 279 | +61 3 9866 4722 | |
| +1 858-966-3003 | Andrew Cohen | ||
| Cheryl Liberatore | +61 408 333 452 | ||
| Director, Communications | |||
| +1 858-966-3045 | |||
| [email protected] |
